NoteHC Andersen Capital has previously received payment from FluoGuide for a Digital IR/Corporate Visibility agreement. This means that there may be paid material that is not updated. See disclaimer.

Log in to your Inderes Free account to see all free content on this page.

FluoGuide

35.8

SEK

+3.47 %

Less than 1K followers

FLUO

First North Stockholm

Medical Equipment & Services

Health Care

Overview

Ownership

Investor consensus

+3.47%

-13.32%

-25.96%

-8.56%

-10.39%

-23.75%

-43.08%

+151.76%

+299.32%

FluoGuide is a Danish company active in medical technology. The company's business focus is found in research and development of treatments against various forms of cancer, with the greatest focus on the development of products that guide surgical interventions. The products bind to the cancer cells, which then light up and are intended to be used to precisely remove harmful tumors in the patient's tissue.

Market cap

487.6M SEK

Turnover

220.36K SEK

Revenue

EBIT %

P/E

Dividend yield-%

Financial calendar

28.5.

2025

Interim report Q1'25

28.8.

2025

Interim report Q2'25

27.11.

2025

Interim report Q3'25

All

Research

Webcasts

Press releases

ShowingAll content types

Regulatory press release3/27/2025, 2:50 PM

Minutes from Annual General Meeting in FluoGuide A/S

Regulatory press release3/12/2025, 8:49 AM

Notice of Annual General Meeting in FluoGuide A/S

Press release2/28/2025, 7:31 AM

Redeye: FluoGuide Q4 2024 - Edging closer to clinical results

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release2/27/2025, 6:03 AM

FluoGuide A/S publishes year-end and annual report for the fiscal year 2024

Regulatory press release2/27/2025, 6:00 AM

FluoGuide A/S publishes interim report for the period January – December 2024

Press release1/15/2025, 3:34 PM

FluoGuide A/S receives approval for phase II trial in head and neck cancer

Press release11/27/2024, 3:05 PM

Redeye: Fluoguide Q3 2024 - Gearing up for high-impact catalysts in 2025e

Regulatory press release11/27/2024, 6:00 AM

FluoGuide A/S publishes interim report for the period January – September 2024

Press release11/19/2024, 12:43 PM

Publication of positive phase II clinical data for FG001 in patients with head and neck cancer

Regulatory press release11/12/2024, 5:23 PM

FluoGuide A/S issue warrants to board member, CMO and CFO

Press release10/21/2024, 2:13 PM

Roger Gunnarsson resigns as board member due to return to a full-time investment banking career, which precludes him from holding board position in FluoGuide

Press release10/7/2024, 11:13 AM

FluoGuide A/S submits Clinical Trial Application for phase II trial in head and neck cancer

Press release8/29/2024, 5:19 PM

Redeye: Fluoguide Q2 2024 - Following the plan

Regulatory press release8/29/2024, 6:55 AM

FluoGuide A/S publishes interim report for the period January – June 2024

Regulatory press release8/26/2024, 7:05 AM

FluoGuide appoints Jens Ellrich as Chief Medical Officer

Regulatory press release6/18/2024, 9:12 PM

FluoGuide has completed a directed share issue to existing and new investors raising proceeds of SEK 60 million

Regulatory press release6/18/2024, 3:31 PM

FluoGuide intends to carry out a directed share issue of approximately SEK 60 million

Press release5/30/2024, 2:51 PM

Redeye: Fluoguide Q1 2024 - Preparing for next steps

Regulatory press release5/30/2024, 6:51 AM

FluoGuide A/S publishes interim report for the period January – March 2024

Press release5/27/2024, 7:40 AM

FluoGuide selects laser system for photothermal cancer therapy with FG001

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.